Novartis Pharmaceuticals' CD20-targeted therapy maintains high efficacy for up to 7 years and can be self-administered by patients.
According to the Chinese financial news app, on September 25th, Novartis Pharmaceuticals (NVS.US) announced two pieces of positive data regarding its monoclonal antibody Kesimpta (ofatumumab) in the research of relapsing multiple sclerosis (RMS). One analysis indicated that in patients with RMS receiving initial treatment, treatment with Kesimpta as a first-line therapy could maintain high efficacy for up to 7 years.
Latest